Zhang Wei, Shu Hongyan, Fang Lixin, Tang Ning, Li Yucai, Guo Bingrong, Meng Fanhui
Department of Thoracic Surgery, Linzi District People's Hospital, Zibo City 255400, China.
Department of Endocrinology, Linzi District People's Hospital, Zibo City 255400, China.
Saudi J Biol Sci. 2020 Apr;27(4):1155-1162. doi: 10.1016/j.sjbs.2019.12.040. Epub 2020 Jan 3.
To minimize the incidence and mortality of cancer, dye trace method was used to explore the mechanism of drug inhibition. 60 mice were selected as the research objects and randomly divided into five groups: model group, shikonin group, aconitine group, notoginsenoside R1 group, and compound group. When establishing the model, begin to administrate the medicine by gavage. The permeability of lung barrier was measured, and H.E staining, immunohistochemical staining, and Western blot test were carried out. The results showed that the mice in model group had decreased autonomic activity, increased permeability of the lung barrier, white nodules on the lung tissue, decreased protein expression related to cell proliferation and differentiation, and decreased protein expression associated with cell proliferation and differentiation, increased expression of related proteins in cancer stem cells, and low level of cell-linked communication. And the incidence of lung cancer in the model group mice was 100%. The histopathological changes in mice were improved to varying degrees after the intervention of the three drugs. Especially in the compound group, the incidence of lung cancer decreased to 8.3%. This study demonstrated that the combination of shikonin, aconitine and notoginsenoside R1 had a good anti-cancer effect, which provided a theoretical basis for clinical research.
为使癌症的发病率和死亡率降至最低,采用染料追踪法探究药物抑制机制。选取60只小鼠作为研究对象,随机分为五组:模型组、紫草素组、乌头碱组、三七皂苷R1组和复方组。造模时开始灌胃给药。检测肺屏障通透性,并进行苏木精-伊红(H.E)染色、免疫组织化学染色和蛋白质免疫印迹(Western blot)检测。结果显示,模型组小鼠自主活动减少,肺屏障通透性增加,肺组织出现白色结节,细胞增殖和分化相关蛋白表达降低,癌症干细胞相关蛋白表达增加,细胞间通讯水平降低。且模型组小鼠肺癌发生率为100%。三种药物干预后,小鼠的组织病理学变化均有不同程度改善。尤其是复方组,肺癌发生率降至8.3%。本研究表明,紫草素、乌头碱和三七皂苷R1联合应用具有良好的抗癌效果,为临床研究提供了理论依据。